secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001477932-23-008275
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

BioNexus Gene Lab receives Nasdaq bid-price deficiency notice
-------------------------------------------------------------

- Closing bid price below $1.00 for 33 consecutive business days (Sept 20 - Nov 3, 2023).
- 180-day compliance period ends May 6, 2024; cure requires $1.00 close for 10 straight days.
- Company may be eligible for an additional 180-day cure period if it meets other listing standards.
- Failure to cure could result in delisting from Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793223008275/0001477932-23-008275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793223008275/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-23-008275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer